Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pharma Q2 Results Preview: Johnson & Johnson And Novartis

Jul 13 2018

• By Jessica Merrill and Kevin Grogan

Abacus — Early reporters Novartis & J&J to reveal their numbers • Source: Shutterstock

Related Content

Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

Apr 09 2018

Real World Data Helping To Drive Rise Of Novartis' Entresto

May 29 2018

CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah

Jul 13 2018

Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?

Jul 13 2018

Alarm As Novartis Exits Antibiotics Space

Jul 12 2018

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

Jul 11 2018

AAA Ramps Up Lutathera Launch And Plans Expansion Under Novartis Ownership

Jul 05 2018

Interview: Measured Launch, Long Future For Gilead CAR-T In Europe

Jul 09 2018

You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments

May 09 2018

Narasimhan Promises To Improve Novartis' Image As Top Lawyer Exits

May 16 2018

Lilly's Taltz Gets Closer To A Level Playing Field With Novartis' Cosentyx

Jun 29 2018

Interview: Novartis Counts On AS and PsA For Cosentyx Growth

Jun 15 2018

Related Companies

Johnson & Johnson

Pfizer Inc.

Merck & Co., Inc.

AbbVie Inc.

Novartis AG

DMK Pharmaceuticals Corp.

Viatris Inc.

Gilead Sciences, Inc.

Eli Lilly and Company

Novartis AG

Additional Topics

Sales & Earnings Companies Launches Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window